Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 16, Number 12—December 2010
CME ACTIVITY - Dispatch

Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus, South Korea

Hwajung Yi, Joo-Yeon Lee, Eun-Hye Hong, Mi-Seon Kim, Donghyok Kwon, Jang-Hoon Choi, Woo-Young Choi, Ki-Soon Kim, Jong-Koo Lee, Hee-Bok Oh, and Chun KangComments to Author 
Author affiliations: Author affiliation: Korea Centers for Disease Control and Prevention, Seoul, South Korea

Main Article

Table 1

Characteristics of 10 patients infected with oseltamivir-resistant pandemic (H1N1) 2009 virus, South Korea, 2009

Patient Age, y/ sex Antiviral treatment and date Date of specimen collection Type of clinical specimen Underlying condition
A 5/M Oseltamivir, 30 mg 2×/d (Oct 29–Nov 4); 60 mg 2×/d (Nov 5–9) Nov 6 Nasopharyngeal swab Mitochondrial cytopathic changes (bedridden)
B 46/M Oseltamivir, 150 mg 2×/d (Nov 6–15); zanamivir, 10 mg 2×/d (Nov 16–26) Nov 18 Nasopharyngeal swab Leukemia
C 1/F Oseltamivir, 30 mg 2×/d (Nov 16–21); 60 mg 2×/d (Nov 22–Dec 8) Nov 21 and 22 Nasopharyngeal swab Brain damage (fatal)
D 2/M Oseltamivir, 90 mg 2×/d (Nov 26–30); 180 mg and amantadine, 65 mg 2×/d (Dec 2–7) Nov 22, Dec 2 Nasal suction None
E 3/F Oseltamivir, 30 mg 2×/d (Dec 1–5 and 7–11) Dec 1, 7, and 9 Oropharyngeal swab (Dec 1, 7); nasopharyngeal swab (Dec 9) Asthma
F 3/F Oseltamivir, 45 mg 2×/d (Dec 10–15); 75 mg 2×/d (Dec 16–20) Dec 18 Oropharyngeal swab Delayed development
G 1/F Oseltamivir, 30 mg 2×/d (Dec 1–5); peramivir, 75 mg 1×/day (Dec 12–18) Dec 1, 5, and 15 Nasal/oropharyngeal swab Myelodysplasia (fatal)
H 63/M Oseltamivir, 150 mg 2×/d (Dec 7–15); zanamivir, 10 mg 2×/d (Dec 16–20) Dec 16 Oropharyngeal swab Diabetes
I 58/M Oseltamivir, 150 mg 2×/d (Dec 16–18); peramivir, 600 mg 1×/d, amantadine, 100 mg 2×/d a day, ribavirin, 300 mg 1×/d (Dec 19–25); zanamivir, 10 mg 2×/d (Dec 26–2010 Jan 1) Dec 26 Nasopharyngeal swab Cancer
J 60/M Oseltamivir, 75 mg 2×/d (Nov 30–Dec 2) Dec 1 Viral RNA Diabetes, cardiac disorders (fatal)

Main Article

Page created: August 28, 2011
Page updated: August 28, 2011
Page reviewed: August 28, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external